United StatesHealth

Intuitive Surgical (NASDAQ:ISRG) hit a major financial landmark Wednesday, reporting preliminary 2025 revenue of $10.06 billion, a 21% increase over the prior year.

The results, fueled by the rapid rollout of the next-generation da Vinci 5 system, underscore the company’s dominant grip on the robotic-assisted surgery market as it transitions from a niche technology provider to a foundational healthcare infrastructure giant.

ImmunityBio (NASDAQ:IBRX) announced Wednesday that the Saudi Food and Drug Authority (SFDA) has approved ANKTIVA® (nogapendekin alfa inbakicept) for the treatment of non-muscle invasive bladder cancer (NMIBC).

Dr. Reddy’s Laboratories (NYSE:RDY) announced Wednesday the first-to-market launch of its over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution, 0.7%, providing a lower-cost generic equivalent to Alcon’s Extra Strength Pataday® Once-Daily Relief.

Emergent BioSolutions (NYSE:EBS) received FDA approval Wednesday for a redesigned, compact carrying case for its over-the-counter (OTC) NARCAN® Nasal Spray, a move aimed at overcoming the "stigma of carrying" that has long hampered community-level overdose responses.

NRx Pharmaceuticals (NASDAQ:NRXP) achieved a pivotal regulatory milestone Wednesday, announcing the submission of a massive real-world dataset to the U.S. Food and Drug Administration (FDA) to support the accelerated approval of NRX-100, its proprietary preservative-free ketamine.

HUTCHMED (China) (NASDAQ:HCM) and partner AstraZeneca (NYSE:AZN) reached a major scientific milestone Wednesday with the publication of full Phase III SACHI trial results in The Lancet.

SEALSQ Corp (NASDAQ:LAES), the semiconductor and post-quantum cryptography subsidiary of WISeKey (NASDAQ:WKEY), announced Wednesday it has entered a non-binding Memorandum of Understanding (MOU) to potentially acquire a majority stake in QUOBLY, a Grenoble-based pioneer in silicon-based quantum computing.

AstraZeneca (NASDAQ:AZN) announced Tuesday at the J.P. Morgan Healthcare Conference that it has acquired Boston-based Modella AI, marking the first time a major pharmaceutical company has fully absorbed a specialized artificial intelligence firm.

ImmunityBio (NASDAQ:IBRX) announced positive results Tuesday from its ANKTIVA® clinical program, signaling a potential paradigm shift in the treatment of advanced non-small cell lung cancer (NSCLC) for patients who have exhausted standard-of-care options.

AudioEye (NASDAQ:AEYE) announced Tuesday its 40th consecutive period of record revenue, signaling that the global push for digital accessibility continues to fuel the company’s expansion.

BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced Tuesday that the first patient in its Bria-OTS trial achieved an 11-month sustained complete resolution of a lung metastasis, providing a significant early validation for the company’s personalized "off-the-shelf" immunotherapy platform.

Fortress Biotech Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, secured a historic regulatory victory Tuesday as the U.S. Food and Drug Administration approved ZYCUBO® (copper histidinate) as the first-ever treatment for Menkes disease.